• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

十六烷基磷胆碱用于乳腺癌患者皮肤转移瘤的局部治疗

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.

作者信息

Unger C, Peukert M, Sindermann H, Hilgard P, Nagel G, Eibl H

机构信息

Department of Internal Medicine, University Hospital, Göttingen, Federal Republic of Germany.

出版信息

Cancer Treat Rev. 1990 Sep;17(2-3):243-6. doi: 10.1016/0305-7372(90)90054-j.

DOI:10.1016/0305-7372(90)90054-j
PMID:2272039
Abstract

Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy. In a phase I trial hexadecylphosphocholine, a new agent with high membrane affinity and antineoplastic activity was applied topically to affected skin areas of breast cancer patients. The results provide evidence that hexadecylphosphocholine may be an active agent in the topical treatment of skin metastases.

摘要

乳腺癌广泛的局部复发无法通过手术或放射治疗进行处理,这主要在对全身治疗无效的患者中构成严重的治疗难题。在一项I期试验中,将具有高膜亲和力和抗肿瘤活性的新型药物十六烷基磷胆碱局部应用于乳腺癌患者的患肤区域。结果证明十六烷基磷胆碱可能是皮肤转移瘤局部治疗的一种有效药物。

相似文献

1
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.十六烷基磷胆碱用于乳腺癌患者皮肤转移瘤的局部治疗
Cancer Treat Rev. 1990 Sep;17(2-3):243-6. doi: 10.1016/0305-7372(90)90054-j.
2
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Onkologie. 1988 Dec;11(6):295-6. doi: 10.1159/000216563.
3
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.十六烷基磷胆碱用于乳腺癌患者皮肤转移瘤的局部治疗
Prog Exp Tumor Res. 1992;34:153-9. doi: 10.1159/000420840.
4
[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].[外用米替福新治疗腿部鳞状细胞癌皮肤转移瘤]
Ann Dermatol Venereol. 2005 Apr;132(4):346-8. doi: 10.1016/s0151-9638(05)79280-2.
5
Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.6%米托蒽醌溶液作为乳腺癌皮肤转移局部化疗药物的随机、双盲、安慰剂对照、多中心试验。
J Clin Oncol. 2001 Nov 1;19(21):4150-9. doi: 10.1200/JCO.2001.19.21.4150.
6
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.米替福新6%溶液局部治疗乳腺癌患者皮肤转移的II期研究。
Anticancer Drugs. 2000 Nov;11(10):825-8. doi: 10.1097/00001813-200011000-00006.
7
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.外用米替福新溶液治疗皮肤转移性乳腺癌患者的II期试验。
Br J Cancer. 1999 Mar;79(7-8):1158-61. doi: 10.1038/sj.bjc.6690184.
8
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.米替福新作为乳腺癌皮肤转移的局部治疗方法。
Cancer Chemother Pharmacol. 1999;44 Suppl:S29-30. doi: 10.1007/s002800051114.
9
Miltefosine in recurrent cutaneous breast cancer.
Lancet. 1997 Mar 1;349(9052):621-2. doi: 10.1016/S0140-6736(05)61570-X.
10
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Acta Oncol. 1989;28(2):213-7. doi: 10.3109/02841868909111249.

引用本文的文献

1
Investigation of miltefosine-model membranes interactions at the molecular level for two different PS levels modeling cancer cells.研究米替福新与两种不同 PS 水平模拟癌细胞的模型膜在分子水平上的相互作用。
J Bioenerg Biomembr. 2024 Aug;56(4):461-473. doi: 10.1007/s10863-024-10025-y. Epub 2024 Jun 4.
2
Evaluation of In Vitro Cytotoxic and Apoptotic Effects of Miltefosine on the RH Strain.米替福新对RH株的体外细胞毒性和凋亡作用评估
Iran J Parasitol. 2024 Jan-Mar;19(1):52-60. doi: 10.18502/ijpa.v19i1.15204.
3
Conditional Knockdown of Osteopontin Inhibits Breast Cancer Skeletal Metastasis.
条件性敲低骨桥蛋白抑制乳腺癌骨转移。
Int J Mol Sci. 2019 Oct 4;20(19):4918. doi: 10.3390/ijms20194918.
4
Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids.秀丽隐杆线虫作为研究合成抗肿瘤脂质作用机制的平台。
Cell Cycle. 2014;13(21):3375-89. doi: 10.4161/15384101.2014.952183.
5
Lysolipid containing liposomes for transendothelial drug delivery.用于跨内皮药物递送的含溶血脂质脂质体。
BMC Res Notes. 2012 Apr 10;5:179. doi: 10.1186/1756-0500-5-179.
6
Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane.糖基化磷脂:质膜信号通路的解偶联。
Br J Pharmacol. 2010 May;160(1):36-47. doi: 10.1111/j.1476-5381.2009.00626.x. Epub 2010 Mar 19.
7
Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.米替福新可诱导杜氏利什曼原虫前鞭毛体发生凋亡样死亡。
Antimicrob Agents Chemother. 2004 Mar;48(3):852-9. doi: 10.1128/AAC.48.3.852-859.2004.
8
[Spectrographic studies on the radioresistance of Miltex and miltefosine].[米替福星和米替福新的辐射抗性的光谱研究]
Strahlenther Onkol. 1997 Apr;173(4):230-5. doi: 10.1007/BF03039292.
9
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.米替福新单独及与铂配合物联合使用对MXT小鼠乳腺癌模型的抗肿瘤活性。
J Cancer Res Clin Oncol. 1993;119(3):142-9. doi: 10.1007/BF01229528.
10
Hexadecylphosphocholine differs from conventional cytostatic agents.十六烷基磷胆碱不同于传统的细胞抑制剂。
J Cancer Res Clin Oncol. 1993;119(9):541-8. doi: 10.1007/BF01686464.